{
    "clinical_study": {
        "@rank": "161587", 
        "acronym": "ASPER", 
        "arm_group": [
            {
                "arm_group_label": "Renal Cancer Group", 
                "description": "For metastatic renal cancer treatments, sunitinib doses are (oral) 50 mg once a day for 4 weeks followed by a two week off period. The six week cycle is then repeated. In case of toxicities observed with the dose, a 25% reduction in the daily dose during the \"on\" period is performed (37.5 mg)."
            }, 
            {
                "arm_group_label": "Colorectal Cancer Group", 
                "description": "Patients receiving BVZ 5mg/kg iv every 2-3 weeks for colorectal cancer"
            }
        ], 
        "biospec_descr": {
            "textblock": "Blood will be drawn to measure blood biomarkers to determine your heart biomarker [High\n      sensitivity TnT and NT-proBNP] as an indicator of early heart failure."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The early detection of BVZ or Sunitinib mediated cardiotoxicity using cardiac biomarkers and\n      novel Transthoracic Echocardiogram (TTE) techniques may allow one to adjust treatment and/or\n      administer prophylactic cardioprotective agents, prior to the development of irreversible\n      cardiac dysfunction. We hypothesize that cardiac biomarkers, TVI/strain-derived indices will\n      be able to accurately detect subtle cardiac injury at a time when conventional Left\n      Ventricular Ejection Fraction (LVEF) remains normal in BVZ or Sunitinib mediated\n      cardiotoxicity. Additionally, we hypothesize that Endothelial Function Test (EndoPAT)\n      testing can detect early BVZ or Sunitinib mediated endothelial dysfunction."
        }, 
        "brief_title": "EARLY DETECTION OF BROKEN HEARTS IN CANCER PATIENTS", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cardiotoxicity", 
        "detailed_description": {
            "textblock": "A total of 100 individuals (50 receiving BVZ and 50 receiving Sunitinib)  will be\n      prospectively enrolled . (80 at Mayo Clinic [40 receiving BVZ and 40 receiving Sunitinib]\n      and 20 at St. Boniface General Hospital (SBGH)). Patients receiving either BVZ 5mg/kg iv\n      every 2-3 weeks for colorectal cancer or Sunitinib 50 mg po daily for advanced Metastatic\n      renal cell carcinoma will be screened for potential eligibility in the study. For metastatic\n      renal cancer treatments, Sunitinib doses are (oral) 50 mg once a day for 4 weeks followed by\n      a two week off period. The six week cycle is then repeated. In case of toxicities observed\n      with the dose, a 25% reduction in the daily dose during the \"on\" period is performed (37.5\n      mg).   Patients will be studied at 7 time points: i) Baseline; ii) Day 1; iii) Day 5; iv)\n      4-6 weeks ; v) 3 months; vi) 6 months after the initiation of both drugs (BVZ and Sunitinib)\n      ; and vii) 12 months after the initiation of BVZ drug only (Figure 1).  Three visits\n      (baseline, 4-6 weeks , and 3 months) are considered part of standard clinical care, and four\n      visits are for research. At each visit, in addition to standard of care provided by the\n      Oncologist, blood will be drawn to measure high sensitivity troponin-T (hsTnT) and\n      Natriuretic-proBNP. The patients will also undergo a TTE with tissue velocity imaging (TVI),\n      strain and left ventricular opacification (LVO) and myocardial perfusion at each time point.\n      EndoPAT test will also be performed at baseline,  and  3 months. The baseline, 4-6 weeks,\n      and 3 month visits will be part of your standard clinical care and followup."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with advanced cancer (colorectal, renal cell, GIST)\n\n          2. Treatment plan includes BVZ or Sunitinib\n\n          3. Ages 18  - 90 years old -\n\n        Exclusion Criteria: Left Ventricular EF < 50%\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "A total of 100 individuals with advanced metastatic renal cell carcinoma or colorectal\n        cancer (50 receiving BVZ and 50 receiving Sunitinib)  will be prospectively enrolled . (80\n        at Mayo Clinic [40 receiving BVZ and 40 receiving Sunitinib] and 20 at St. Boniface\n        General Hospital (SBGH))."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086695", 
            "org_study_id": "12-005362"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chemotherapy", 
            "Cardiotoxicity"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "smulvagh@mayo.edu", 
                    "last_name": "Sharon L Mulvagh, M.D.", 
                    "phone": "507-284-9601"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Sharon L Mulvagh, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "djassal@sbgh.mb.ca", 
                    "last_name": "Davinder S. Jassal, M.D.", 
                    "phone": "2042372023"
                }, 
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba", 
                        "zip": "R2H 2A6"
                    }, 
                    "name": "St. Boniface General Hospital"
                }, 
                "investigator": {
                    "last_name": "Davinder S. Jassal, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_groups": "2", 
        "official_title": "EARLY DETECTION OF BROKEN HEARTS IN CANCER PATIENTS: BEVACIZUMAB, SUNITINIB AND HEART FAILURE", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with changes  in Tissue velocity imaging (TVI), myocardial deformation indices (Strain, strain rate, twist and torsion), and diastolic function indices (Mitral Valve Pulsed Wave Doppler, Tissue Doppler Imaging, Left Atrial volumes)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086695"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Sharon Mulvagh", 
            "investigator_title": "Consultant of Cardiology Noninvasive", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with changes in quantitative  myocardial perfusion parameters including myocardial blood flow velocity and myocardial blood flow derived from contrast perfusion echocardiography", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 2 years"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Asper Foundation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "St. Boniface General Hospital Research Centre", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Lantheus Medical Imaging", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}